Indian Pharma industry moving towards formulations

Indian Pharma industry is slowing moving up the value chain. Earlier it used to manufacture active pharmaceutical ingredient at low cost compared to world. Now with competition from China, which provides API at 15-20% low cost, it makes sense to shift focus elsewhere. Many top companies like Lupin, Novartis, Ranbaxy have less revenue stream from API than from formulations. There could also be the reason that formulation business has grown faster than APIs for some companies. API is low scale commodity with low margin. Moreover, with a large number of patent expiries in developed markets like the US and Europe, Indian companies, with skills to develop and manufacture low-cost generic drugs, see a much more lucrative opportunity there than utilising their capacities for manufacturing APIs.
Read More

  • No Image
    Torrent Pharmaceuticals Ltd

    Torrent Pharma, the flagship company of Torrent Group, is ranked amongst the top pharma companies of India. It is a dominant player in the therapeutic areas of cardiovascular (C

  • No Image
    Trimurthi Drugs And Pharmaceuticals Ltd

    Trimurthi Drugs and Pharmaceuticals Ltd., is a listed company at Bombay Stock exchange, profit making and dividend paying company, also an ISO 9001:2008 certified.The Company is

  • No Image
    TTK Healthcare Ltd

    TTK Healthcare is committed to providing customers with innovative "value for money" solutions and improving their quality of life.

    The Company's brand wagon consists of